RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CIDY vs THTX..Remember, they got tesamorelin approved, but failed to get substantial profit out of it, either alone or with Serono, so they were a prove it company when they acquired the right to ibalizumab. After approval I thought it was the proof of a succesful company. I made a mistake. It was a scientific success, but again, a commercial failure. So I agree we are back in the prove it zone, but I think the bar will be relatively higher this time. Skepticism is in full force. They will need very good results in cancer relatively quickly, otherwise the road will likely be long. On the NASH front, I don't know if it can drive the stock price in the short term. Possible approval would be in 2024 at best. Unless they can convinced some big investor to buy, or some really start to make valuation comparisons with other NASH companies. I don't know.
Wino115 wrote: It's been said many times here, but they have been relegated to "Prove It" territory, so we need solid fundamental developments to underpin valuation. That should get it moving the right direction.
Definitely tax selling. I had some small below market orders at $2.10 that got hit toward end of day. A lot of times, they alot a certain number of shares a day and rush to meet them at the end.....and then start again tomorrow! We should only have another 7 trading days in the year so it's just about over.
Adonis wrote: I want just to know who selling at this price..!??